At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Memorial Sloan Kettering offers language assistance services for those who prefer to receive health information in another language. Learn more about our language assistance program here.
-
Researchers are studying how casdatifan, alone or with zimberelimab, works in people with kidney cancer. The people in this study have clear cell renal cell carcinoma. Their cancers have metastasized (spread) or are inoperable (cannot be taken out with surgery).
-
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
-
Researchers want to find the best dose of DS-2243a to use in people with solid tumors. The people in this study have these solid tumors, which have spread beyond their original location:
-
Researchers want to find the best dose of RMC-9805 to use in people with advanced solid tumors. The people in this study have cancer that keeps growing even with treatment. The tumors also have a mutation (change) in the KRAS gene called G12D.
-
Researchers want to find the best dose of eganelisib when used alone and with cytarabine to treat leukemia. The people in this study have acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS) that has come back or keeps growing after treatment.          
-
A standard approach for early-stage rectal cancer is treatment with chemotherapy and radiation therapy followed by surgery. In this study, researchers are comparing two approaches to prevent the need for rectal resection (removal of all or nearly all of the rectum) in people with early rectal cancer: chemotherapy or chemotherapy and radiation with observation or limited surgery (removing only the area with the tumor, not the entire rectum).
-
Researchers want to find the best dose of Debio 0123 that can be given with temozolomide to treat glioblastoma. Glioblastoma is a type of brain cancer. The people in this study have glioblastoma that keeps growing even after treatment.
- A Phase 1-2 Study of Belumosudil in Children and Adolescents With Chronic Graft-Versus-Host Disease
Full Title An Open-label, Phase 1/2, Multicenter Study of Belumosudil in Children Aged 1 to 18 Years Requiring Systemic Treatment for Active Moderate-to-severe Chronic Graft Versus Host Disease (cGVHD)
Purpose
Chronic graft-versus-host disease (cGVHD) is a condition in which healthy transplanted stem cells attack the recipient’s healthy cells. cGVHD most often happens more than 100 days after a stem cell transplant, but it can happen at any time.
Belumosudil is an oral medicine (taken by mouth) already used to treat adolescent and adult patients with cGVHD. Researchers want to find the best dose of belumosudil for children with cGVHD and learn how well it treats cGVHD in younger patients.
Eligible patients have cGVHD that is resistant to or has returned after at least 2 lines of systemic therapy. Systemic therapy is a type of treatment that works throughout the whole body.
Belumosudil blocks proteins involved in cGVHD. It helps control the immune system, reducing its ability to attack the body after a transplant and decreasing tissue damage.
Who Can Join
To join this study, there are a few conditions. Your child must:
- Have cGVHD that is resistant to or has returned after at least 2 lines of systemic therapy.
- Be age 1-17.
Contact
For more information about this study or to see if your child can join, please call 833-MSK-KIDS.
Protocol
25-194Phase
Phase I/II (phases 1 and 2 combined)Investigator
Co-Investigators
Diseases
Locations
ClinicalTrials.gov ID
NCT07116031ClinicalTrials.gov
-
Researchers want to see how well selinexor works in people with Wilms' tumor and other solid tumors. The people in this study are children and adults with tumors that depend on a protein called XPO1. XPO1 helps cancer cells grow by getting rid of proteins that can cause those cells to die (tumor suppressor proteins).
-
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.